EV/EBITDA Multiple: Carmell Corp (CTCX)

Corporate company logo of carmellrx.com (CTCX)

The current market value of Carmell Corporation (CTCX) plotted on this chart, where the EV/EBITDA ratio equals , correlates with international patent law risks and logistical complexities in component delivery. Carmell Corporation is implementing automated polymer printing stations and data analysis software for tissue engineering. The business relies on the supply of unique plasma biomaterials, which ensure stable demand within the surgical sector.

CTCX (Carmell Corp.) Enterprise Value to Operating Income Before Depreciation Ratio history from 07/04/2022 to 11/15/2026

Carmell Corp. (CTCX) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:CTCX (Carmell Corporation)
Product sample of Carmell

For Carmell Corporation (CTCX), whose valuation depends on the commercialization of plasma materials, controlling the business value relative to operating profit is critical. This indicator aggregates market capitalization and net debt, dividing them by EBITDA, which reflects the change in the EV/EBITDA ratio over time. Analyzing this trend allows an investor to assess the efficiency of marketing expenditures and avoid purchasing overvalued assets.

Who Carmell Corporation competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences, Inc. SGMT|BioAge - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion Corp - EV/EBITDA Multiple|QNCX - EV/EBITDA Multiple|GUTS: EV/EBITDA Multiple|VTVT (vTv Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Agape ATP Corp.|PLUR: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Synlogic, Inc. (SYBX)|Enterprise Value to EBITDA Ratio Lipocine Corp LPCN|EV/EBITDA Multiple MTNB (Matinas BioPharma Holdings, Inc.)|Spruce Biosciences (SPRB) - Company Value to EBITDA|GLTO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation